OPTHEA
LIVE

Serial Number

79210373

Owner

Opthea Limited

Attorney

Richard M. LaBarge

Filing Date

Dec 7, 2016

Add to watchlist:

No watchlists yet
View on USPTO

OPTHEA Trademark

Serial Number: 79210373 • Registration: 5477686

OPTHEA is a trademark filed by Opthea Limited on December 7, 2016. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Opthea Limited (2 trademarks)

S0403 L4,
SOUTH YARRA VIC 3141 , AU

Entity Type: 03

Trademark Details

Filing Date

December 7, 2016

Registration Date

May 29, 2018

Published for Opposition

March 13, 2018

Cancellation Date

February 10, 2026

Goods & Services

[ Advisory services relating to scientific research; Laboratory services, namely, scientific research or analysis in the field of ophthalmology; Management of scientific research projects; Medical research and scientific research for medical purposes; Preparation of reports relating to scientific research; Preparation of scientific reports; Providing information, including online, about scientific and technological services and research and design relating thereto, namely for scientific research, analyses and testing in the field of ophthalmology; Provision of information relating to scientific research; Provision of scientific information in the field of ophthalmology; Scientific advisory services in the field of ophthalmology; Scientific analysis in the field of ophthalmology; Technical analysis for research and testing in the field of ophthalmology; Scientific and technological services namely for scientific research, analysis and testing in the field of ophthalmology; Scientific consultancy relating to ophthalmic conditions; Scientific laboratory services; Scientific research; Scientific research in the field of pharmacy; Scientific research into the development of new products; Scientific research relating to bacteriology; Scientific research relating to biology; Scientific research relating to chemical products; Scientific research relating to chemistry; Scientific research relating to genetics; Scientific testing services in the field of ophthalmology; Bacteriological research; Biochemistry research services; Biological research; Biotechnological research; Biotechnology research; Chemical research; Chemical technological research; Genetic research; Laboratory research; Medical research; Pharmaceutical research services; Providing information, including online, about industrial analysis and research services namely for scientific research, analyses and testing in the field of ophthalmology; Provision of medical, veterinary, biological and pharmaceutical research services in the field of ophthalmology; Research and development of new products for others; Research and development of products; Research into the development of new products; Research laboratories in the field of ophthalmology; Research relating to bacteriology; Research relating to biotechnology; Research relating to chemicals; Research relating to chemistry; Research relating to medicine; Research relating to molecular sciences; Research relating to pharmaceuticals; Research relating to science; Research to develop new products; Services for assessing the efficiency of pharmaceuticals namely pharmaceutical product evaluation; Services for assessing the safety of pharmaceuticals, namely testing, inspection or research of pharmaceuticals; Chemical analysis; Laboratory analysis in the field of ophthalmology; Analysis of tissues for medical research; Design of medical apparatus; Medical laboratory services; Analytical laboratory services, namely analysis of tissue samples or bodily fluids for diagnostic purposes; Chemical laboratory services; Laboratory testing services, namely testing of tissue samples or bodily fluids for diagnostic purposes; Veterinary laboratory services; Information in the field of chemical research; Testing of chemicals ]

Biological preparations for pharmaceutical purposes for the treatment of ophthalmic conditions; [ Chemical preparations for pharmaceutical purposes for the treatment of ophthalmic conditions; Chemical products, namely, sugars, proteins and nucleic acids for pharmaceutical use for the treatment of ophthalmic conditions; Chemicals for pharmaceutical use for the treatment of ophthalmic conditions; Pharmaceutical compositions for the treatment of ophthalmic conditions; Pharmaceutical creams for the treatment of ophthalmic conditions; Pharmaceutical drugs for the treatment of ophthalmic conditions; ] Pharmaceutical preparations for the treatment of ophthalmic conditions [ ; Pharmaceutical preparations for animals for the treatment of ophthalmic conditions; Pharmaceutical preparations for human use for the treatment of ophthalmic conditions; Pharmaceutical preparations for personal use for the treatment of ophthalmic conditions; Pharmaceutical preparations for veterinary use for the treatment of ophthalmic conditions; Pharmaceutical products for the treatment of ophthalmic conditions; Pharmaceutical products for use by humans for the treatment of ophthalmic conditions; Pharmaceutical substances for the treatment of ophthalmic conditions; Veterinary medicaments for the treatment of ophthalmic conditions; Veterinary preparations for the treatment of ophthalmic conditions; Veterinary products for the treatment of ophthalmic conditions; Biological preparations for medical purposes for the treatment of ophthalmic conditions; Biological preparations for use in biotechnology for the treatment of ophthalmic conditions; Biological preparations for use in cell cultures, namely in culture media for cultivating human, animal, plant or microorganism cells for medical use; Biological preparations for veterinary purposes for the treatment of ophthalmic conditions; Biological products for medical use, namely for the treatment of ophthalmic conditions; Biological reagents for use in molecular biology for medical use; Biological substances for medical use, namely, biologics, antibodies, monoclonal antibodies, cells and cellular tissues for medical use, namely for the treatment of ophthalmic conditions; Biological tissue cultures for medical purposes; Biological tissue cultures for veterinary purposes; Chemical products, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for use in biology for medical or veterinary use, namely for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Therapeutic biological products, namely, biologics, antibodies, monoclonal antibodies, cells and cellular tissues for medical use, namely for the treatment of ophthalmic conditions; Medical preparations for the treatment of ophthalmic conditions; Substances for use in genetic probe assay kits for medical use, namely, medical diagnostic reagents and assays for testing body fluids; Substances for veterinary use produced by genetic engineering, namely, genetically engineered tissues for transplant purposes; Cultures of cell media for medical use; Cultures of cell media for veterinary purposes; Chemical products for medical or veterinary laboratory use, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical preparations for medical analysis purposes, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical preparations for medical purposes for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical preparations for veterinary purposes, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical products for analysis for medical purposes, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical products for analysis for veterinary purposes, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical products for biotechnological purposes for medical uses, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical products for biotechnological purposes for veterinary use, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical products for medical or veterinary diagnostic purposes, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical products for medical diagnostic use, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical products for veterinary diagnostic use, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical products for medical use, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical products for use in medical science, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical products for use in science for medical or veterinary purposes, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemicals for use in medical and veterinary analysis , namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions ]

Filing History

NOTICE OF CANCELLATION SEC. 71 E-MAILED
Feb 10, 2026 NC71
CANCELLED SECTION 71
Feb 10, 2026 C71T
POST REGISTRATION ACTION MAILED - SEC.71
Jul 28, 2025 PR71
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Jul 7, 2025 EROP
POST REGISTRATION ACTION MAILED - SEC.71
Jan 4, 2025 PR71
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Dec 26, 2024 APRE
TEAS SECTION 71 RECEIVED
May 22, 2024 ES71
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
May 29, 2023 REM3
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Dec 15, 2022 LIMN
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
Dec 3, 2022 RHRD
NEW REPRESENTATIVE AT IB RECEIVED
Jan 2, 2021 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 28, 2018 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 12, 2018 FICS
FINAL DISPOSITION PROCESSED
Sep 12, 2018 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 29, 2018 FICR
REGISTERED-PRINCIPAL REGISTER
May 29, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 13, 2018 NPUB
PUBLISHED FOR OPPOSITION
Mar 13, 2018 PUBO
NOTIFICATION PROCESSED BY IB
Mar 9, 2018 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 21, 2018 OPNS
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 21, 2018 NONP
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 21, 2018 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 6, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 9, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 8, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 8, 2018 TROA
REFUSAL PROCESSED BY IB
Jul 28, 2017 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 6, 2017 RFCS
REFUSAL PROCESSED BY MPU
Jul 6, 2017 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 30, 2017 RFCR
NON-FINAL ACTION WRITTEN
Jun 29, 2017 CNRT
APPLICATION FILING RECEIPT MAILED
Jun 27, 2017 MAFR
ASSIGNED TO EXAMINER
Jun 23, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 23, 2017 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 22, 2017 REPR